Recent Updates — VNRX
VolitionRx Limited prepaid $500,000 in cash toward the outstanding principal balance of its senior secured convertible promissory note issued to Lind Global Asset Management XII LLC. Following this partial prepayment, the remaining balance on the $2.4 million note is reduced to $706,667. In connection with the transaction, Lind agreed to defer monthly repayments for November and December 2026 and waived its conversion rights until January 1, 2027, unless the stock price reaches at least $0.275 per share. This brings total debt reduction across both notes held by Lind to over $5.0 million since June 30, 2026. VolitionRx Limited is a multi-national epigenetics company developing blood tests for early disease detection and monitoring.
VolitionRx Limited issued shares of common stock to Lind Global Asset Management XII LLC to satisfy conversion obligations under senior secured convertible promissory notes. On September 2, 2026, the company issued 706,214 shares to settle a $250,000 obligation, and on September 10, 2026, it issued 707,236 shares to satisfy a $215,000 obligation. As of September 14, 2026, there were 27,903,326 shares of common stock issued and outstanding. VolitionRx Limited operates in the healthcare diagnostics industry, developing molecular diagnostic tests for cancer detection.
VolitionRx Limited prepaid in cash approximately $422,000 on September 11, 2026, satisfying the outstanding balance of its senior secured convertible promissory note originally issued for $7,500,000 to Lind Global Asset Management XII LLC. This early retirement eliminates potential future equity dilution associated with the conversion of the 2025 Note. The company's second note to Lind, originally $2,400,000, remains outstanding with a balance of approximately $2,041,667. VolitionRx Limited is a multinational epigenetics company developing and commercializing blood tests for early disease detection and monitoring.
VolitionRx Limited entered into a Waiver and Consent with Lind Global Asset Management XII LLC on September 2, 2026. This agreement waives covenant breaches related to the Company's At-The-Market (ATM) sales exceeding the $10 million annual cap under its Securities Purchase Agreement dated May 15, 2025. Lind consented to treat ATM sales in excess of the limit as Permitted ATM Sales and waived remedies for Events of Default triggered by these sales. The waiver also adjusts the conversion price of the senior secured convertible promissory notes ($9.9 million total principal) and exercise prices of associated warrants based on ATM sales through August 28, 2026. VolitionRx Limited operates in the healthcare diagnostics industry, developing molecular diagnostic tests for cancer detection.
VolitionRx Limited issued a total of 4,778,728 shares of common stock to Lind Global Asset Management XII LLC between August 27 and August 31, 2026. These issuances satisfied conversion obligations totaling $1,715,000 under senior secured convertible promissory notes originally issued in May 2025. The transactions were conducted pursuant to a securities purchase agreement and relied on exemptions from registration under Section 4(a)(2) of the Securities Act or Regulation D. VolitionRx Limited operates in the healthcare diagnostics industry, developing molecular diagnostic tests for cancer detection.